Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.

New agents, alone or in combination with ruxolitinib, are currently under clinical trial investigation (ClinicalTrials.gov) and preliminary results were presented at the 2022 ASH annual meeting and highlighted in the current review.